PDGFRB and neoplasm: In almost all resistant tumours the MAPK pathway is reactivated either via activating mutations or amplification in BRAF, MEK1/2 or NRAS or via the transcriptomic upregulation of receptor tyrosine kinases, including PDGFRß and c-MET2,16.